107PDAFATINIB (A) PLUS PACLITAXEL (P) FOLLOWING PROGRESSION ON A MONOTHERAPY IN PATIENTS (PTS) WITH METASTATIC NON–SMALL-CELL LUNG CANCER (NSCLC) WHO PREVIOUSLY BENEFITED FROM ERLOTINIB (E)/GEFITINIB (G): A GLOBAL RANDOMISED PHASE III TRIAL–LUX-LUNG 5 (LL5)


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles